Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

John S Dowden
Med J Aust 2004; 180 (6): . || doi: 10.5694/j.1326-5377.2004.tb05940.x
Published online: 15 March 2004

John S Dowden

  • John S Dowden

  • Australian Prescriber, Suite 3/2 Phipps Close, Deakin, ACT 2600.


Competing interests:

Australian Prescriber is published by the National Prescribing Service. John Dowden is an unpaid director of Therapeutic Guidelines Ltd, and a member of the Editorial Advisory Board of the Australian Medicines Handbook.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.